Corvus Pharmaceuticals to Present Updated Data from its Clinical Trial of CPI-006 for Patients with COVID-19 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
The updated data from the COVID-19 program will be presented in a poster at SITC:
|Title:||Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells|
The SITC poster presentation will be available on the SITC meeting website from
R&D Symposium Conference Call, Webcast and Presentation Slides
Corvus will host an R&D Symposium on
Tullia C. Bruno, PhD, Assistant Professor, Department of Immunologyat UPMC Hillman Cancer Center. Dr. Brunowill provide an overview of B cell biology and antibodies. Gerard J. Criner, M.D., Chair and Professor, lead investigator of the CPI-006 COVID-19 Phase 1 study, and Chair and Professor, Thoracic Medicine and Surgery at the Lewis Katz School of Medicineat Temple University. Dr. Crinerwill provide an overview of current COVID-19 therapies.
Members of the Corvus team will provide an overview of the preclinical biology and data on CPI-006, updated data from the CPI-006 Phase 1 study for patients with COVID-19, and a general pipeline update covering the Company’s cancer programs. The speakers will be available for questions and answers during the program.
The R&D Symposium conference call can be accessed by dialing 1-877-423-9813 (toll-free domestic) or 1-201-689-8573 (international) and using the conference ID 13712583. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 days.
About Corvus Pharmaceuticals
Chief Financial Officer
Source: Corvus Pharmaceuticals, Inc.